LRMR News and Press, Larimar Therapeutics Inc.

2024-06-06 10:13:02 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Bird flu death in Mexico linked to strain not seen in humans before FDA advisors unanimously agree on COVID JN.1-lineage vaccine for fall Moderna...

2024-05-31 16:11:42 ET Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $...

2024-05-30 18:23:09 ET More on Larimar Therapeutics Larimar stock rallies 24% on FDA removal of partial clinical hold Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larim...

START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development pro...

2024-05-29 08:45:00 ET Growth stocks have been outpacing value and dividend stocks since 2008, and this performance gap has only widened as the pandemic's impact has waned. Technological breakthroughs are opening new markets in high-demand areas, fueling investor interest in a wide array of...

2024-05-26 06:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-21 16:15:01 ET William Blair analyst issues OUTPERFORM recommendation for LRMR on May 21, 2024 02:39PM ET. The previous analyst recommendation was Outperform. LRMR was trading at $7.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-05-21 13:30:04 ET William Blair analyst issues HOLD recommendation for LRMR on May 21, 2024 11:55AM ET. The previous analyst recommendation was Hold. LRMR was trading at $8.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-05-21 05:45:39 ET More on related stocks: Palo Alto Networks Q3 Earnings: Moving From Star Performer To Fallen Angel (Rating Downgrade) Palo Alto Networks, Inc. (PANW) Q3 2024 Earnings Call Transcript Palo Alto Networks, Inc. 2024 Q3 - Results - Earnings Call Pr...

2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...